Tag

Tirzepatide

All articles tagged with #tirzepatide

FDA Escalates Recall of Compounded Tirzepatide Injections from Apothecary Pharma

Apothecary Pharma LLC has voluntarily recalled 22 vials of compounded tirzepatide injections nationwide due to sterility concerns. The FDA upgraded the recall to Class II on October 10, 2026, following a December 2025 warning letter citing serious deficiencies that put patients at risk. While the risk of serious harm is considered small, users are advised to stop using affected lots and contact prescribers for disposal instructions.

via USA Today|

#compounding-pharmacies #fda-actions #glp-1-recalls

health6 days ago•6 min saved

GLP-1 Drugs May Slow Biological Aging by Up to Four Years, But Experts Cautious

New research suggests GLP-1 medications like tirzepatide and semaglutide may slow biological aging by two to six years, potentially extending lifespan. However, experts warn that benefits for healthy, non-obese individuals remain unproven, and it is unclear if effects stem from weight loss or the drugs themselves.

via CNN|

#anti-aging #biological-age #glp-1-drugs

health1 month ago•4 min saved

Debate at Brazilian Endocrinology Congress Questions If GLP-1 Therapy Should Be Lifelong

At the 37th Brazilian Congress of Endocrinology and Metabolism, experts debated whether GLP-1 receptor agonists should be lifelong treatments. While some argue indefinite use is necessary to prevent weight regain and maintain cardiometabolic benefits, others advocate for individualized tapering or discontinuation for patients who maintain weight through lifestyle changes. Recent data suggests these drugs primarily reduce fat while preserving muscle, though long-term safety and access remain critical concerns.

via Medscape|

#cbem-2026 #glp-1-receptor-agonists #health

health1 month ago•20 min saved

GLP-1 Weight Loss Drugs Linked to Rare, Fatal Brain Disorder

A new study links popular GLP-1 weight-loss drugs to a rare, potentially fatal brain disorder called Wernicke encephalopathy. The condition, caused by vitamin B1 deficiency, can lead to permanent brain damage or death if untreated. While the risk is low, experts urge clinicians to monitor patients for symptoms, especially those experiencing gastrointestinal issues or malnutrition.

via New York Post|

#glp-1 #health #semaglutide

health1 month ago•2 min saved

Tirzepatide Outperforms Semaglutide in Weight Loss but Carries Higher Risk of Serious Side Effects

A new meta-analysis of 41,381 adults with overweight or obesity found that tirzepatide produces significantly greater weight loss and better blood sugar control than semaglutide. However, this efficacy comes with a trade-off: patients on tirzepatide experienced serious adverse events at a rate of 5.7%, compared to 2.9% for those on semaglutide. While discontinuation rates due to side effects did not differ significantly between the two groups, the higher incidence of serious events suggests clinicians must carefully balance efficacy against safety profiles when prescribing incretin-based therapies.

via Medscape|

#clinical-trials #health #obesity-treatment

health2 months ago•5 min saved

New Data Suggests Tirzepatide Causes More Hair Loss Than Semaglutide

A pre-publication study from nference Labs indicates that tirzepatide (Zepbound/Mounjaro) is associated with a higher rate of hair loss than semaglutide (Ozempic/Wegovy). Among 8,985 female patients, 5.44% of tirzepatide users developed alopecia compared to 3.63% of semaglutide users over 12 months. Experts note that while weight loss contributes to shedding, the difference persists even after matching patients by weight loss, suggesting the drugs themselves may affect hair follicles differently. The findings are observational and not yet peer-reviewed, but dermatologists advise monitoring for persistent shedding or scalp inflammation.

via Women's Health|

#dermatology #glp-1 #hair-loss

health2 months ago•48 min saved

19-Year-Old Student Dies After Using Common GLP-1 Weight-Loss Drug

A 19-year-old law student from Corona, California, died in a London dorm after taking tirzepatide, a widely prescribed GLP-1/GIP weight‑loss drug sold as Mounjaro and Zepbound. An inquest found her death was due to cardiac arrhythmia, with doctors noting a congenital heart condition (myocardial bridging) that may have contributed; vomiting could have triggered electrolyte imbalances leading to the arrhythmia. Nasr had been prescribed Zepbound by a U.S. doctor and was not obese, highlighting potential risks associated with GLP-1 therapies.

via Yahoo|

#cardiac-arrhythmia #glp-1-drugs #health

health2 months ago•7 min saved

College Student Dies After Using tirzepatide Weight-Loss Drug

A 19-year-old California college student died in her London dorm after taking tirzepatide, a GLP-1/GIP receptor agonist marketed for weight loss as Mounjaro and Zepbound; the incident comes amid rising use of GLP-1 weight-loss meds in the U.S. (about 15% have tried such medications) and ongoing safety discussions.

via The Daily Beast|

#collegestudentdeath #drugsafety #glp-1

health2 months ago•4 min saved

Mounjaro linked to lower heart attack risk in diabetics with heart disease

An observational study of about 53,000 people with type 2 diabetes and established heart disease found tirzepatide (Mounjaro) was associated with a 33% lower risk of major cardiovascular events, including heart attack, over roughly one year compared with sitagliptin; 2.9% vs 4.4% event rates, roughly one event prevented per 70 new tirzepatide users. The findings add to evidence GLP-1 meds may support heart health, but the study’s observational design and short follow-up limit conclusions, and tirzepatide is not FDA-approved for cardiac risk reduction.

via Healthline|

#glp-1 #health #heart-attack

health2 months ago•4 min saved

Coroner Cites Tirzepatide-Induced Electrolyte Imbalance in Student's Death

British coroner Graeme Irvine linked 19-year-old Josephine Nasr’s death in London to a cardiac arrhythmia associated with congenital heart disease and electrolyte imbalance caused by tirzepatide, a weight-loss/diabetes drug she had been prescribed in California. The inquest noted nausea from tirzepatide can trigger hypoglycemia and electrolyte disturbances that provoke dangerous arrhythmias, and the autopsy found a congenital heart condition; tirzepatide is not approved for under-18s and is associated with serious GI side effects.

via Where Is The Buzz|

#cardiac-arrhythmia #coroner-inquest #electrolyte-imbalance

health2 months ago•48 min saved

UK Coroner Ties Tirzepatide to Death of California Law Student

A British coroner ruled that tirzepatide contributed to the death of Josephine Nasr, a 19-year-old American law student at the University of East London, finding that a cardiac arrhythmia linked to a congenital heart condition and electrolyte imbalance from tirzepatide-induced hypoglycemia led to her death; an empty tirzepatide vial was found near her body, and Nasr had experienced nausea before she died. Eli Lilly warns the drug is not approved for cosmetic weight loss or for under-18 patients.

via Yahoo|

#cardiac-arrhythmia #coroner #electrolyte-imbalance

world2 months ago•24 min saved

Coroner links California student’s London death to Tirzepatide weight-loss drug

A 19-year-old California law student, Josephine Nasr, studying at the University of East London, was found dead in her dorm in September 2025. An inquest concluded the death was a cardiac arrhythmia caused by an electrolyte imbalance from hypoglycemia, triggered by Tirzepatide (Mounjaro/Zepbound), a prescribed weight‑loss drug; autopsy noted a congenital heart condition (myocardial bridging) that may have contributed, and an empty Tirzepatide vial was found at the scene.

via New York Post|

#arrhythmia #california #inquest

health2 months ago•13 min saved

UK Records Near-200 Deaths Linked to GLP-1 Weight-Loss Drugs, Regulator Cautions on Causation

UK MHRA Yellow Card data show roughly 200 deaths linked to GLP-1 obesity drugs (about 59 with semaglutide Ozempic/Wegovy, 120 with tirzepatide Mounjaro, 37 with liraglutide Saxenda) and over 150,000 adverse reactions. The regulator notes that reportings do not prove causation and many deaths may be due to underlying illnesses, while emphasizing GLP-1 medicines are safe for the majority of users; examples in investigations include deaths of Caroline Savage and Paula Owen.

via The Times of India|

#adverse-reactions #glp-1-weight-loss-drugs #health

health2 months ago•3 min saved

Women shed more weight than men on GLP-1 drugs like Mounjaro, study finds

A study in Obesity reports that overweight or obese women on tirzepatide (Mounjaro) lost about 15% of body weight after 15 months, compared with ~11% for men. While younger participants (<45) tended to lose more, age wasn’t the strongest predictor. Greater weight loss occurred among those without Type 2 diabetes, who hadn’t used weight‑loss meds before, and at higher doses. Possible explanations include slower drug clearance in women and estrogen’s effects; broader meta-analyses also show women often lose more weight on GLP-1 therapies.

via New York Post|

#glp-1 #health #study

health3 months ago•9 min saved

GLP-1 Weight Drugs May Dampen Binge Eating Symptoms, Review Finds

A meta-analysis of 25 RCTs (n=8,069) finds GLP-1 receptor agonists used for weight loss—such as semaglutide, tirzepatide, and liraglutide—also reduce binge eating, loss-of-control eating, and emotional eating beyond weight loss, while dietary restraint tends to rise. Researchers caution that most trials had bias and limited BED-diagnosed samples, and emphasize integrating medication with psychological therapy and social support, plus addressing public-access barriers. More independently funded, long-term studies are needed to confirm clinical utility.

via Neuroscience News|

#binge-eating-disorder #glp-1-receptor-agonists #health